Frederick Dorey

Special Counsel
Full contact info

Experience

Cooley advises Pivot Bio on $430 Million Series D Financing

August 27, 2021

Cooley advised California-based agricultural biotech growth company Pivot Bio on its $430 million Series D funding round. Pivot Bio has raised over $600 million to date and plans to use the funds to scale-up its microbial nitrogen technology that helps farmers boost crop yield and reduce reliance on synthetic nitrogen fertilizer. The funding will also be used to help the company expand internationally. “We have earned the trust of farmers for our direct-to-grower approach and have proven that our products provide consistent yields and profits for farmers, even in the face of a volatile climate,” said Karsten Temme, Ph.D., CEO and co-founder of Pivot Bio, in a news release.

Related contacts

Frederick Dorey
Special Counsel, Palo Alto

Related Practices & Industries

Cooley advises Inflammatix on $102M Series D Round

March 24, 2021

Cooley advised Inflammatix, a pioneering molecular diagnostics company, on its $102 million Series D funding round to support the development and commercialization of the company’s novel immune response diagnostics portfolio. D1 Capital Partners led the round, with participation from the company’s existing investors, including Northpond Ventures, Khosla Ventures, Think.Health, and OSF Healthcare Ventures. Inflammatix’s diagnostics rapidly read the patient’s immune response to infections across multiple mRNA biomarkers using machine learning algorithms. The company’s tests can identify the presence and type of infection (viral or bacterial), and the risk of severe disease, including severe COVID-19, to enable physicians to make more informed decisions. The funds will enable regulatory clearance and global commercialization of the Myrna system, and the InSep™ acute infection and sepsis test, which is designed to enable improved triage and decision-making in the emergency department and other acute care settings. 

Related contacts

Frederick Dorey
Special Counsel, Palo Alto
Anita Vasudevan
Special Counsel, Palo Alto

Related Practices & Industries

Cooley advises Pivot Bio on $100M Series C Round

May 4, 2020

Cooley advised California-based agricultural biotech growth company Pivot Bio on its $100 million Series C funding round, co-led by repeat investors Breakthrough Energy Ventures and a global investment company. Pivot Bio has raised $186 million to date and plans to use the funds to scale-up its microbial nitrogen technology that helps farmers boost crop yield and reduce reliance on synthetic nitrogen fertilizer. The funding will also be used to help the company expand internationally. "The strong backing by our Series C investors enables Pivot Bio to redefine the future of fertilizer and provide the world's farmers with a new nitrogen source. Based on remarkable demand, we expect to ramp up from our large current footprint to millions of additional acres in the next growing season." said Karsten Temme, Ph.D., CEO and co-founder of Pivot Bio, in a news release.

Related contacts

Frederick Dorey
Special Counsel, Palo Alto
John Sellers
Partner, Palo Alto
Emily Iannarelli
Associate, Palo Alto
Lauren Creel
Partner, Palo Alto
Chris Holly
Partner, Washington, DC
Judd Lauter
Special Counsel, San Francisco
Karen Gustavson
Associate, Seattle

Admissions and credentials

California

District of Columbia